Sign in or create an account to add this stock to your watchlist.
About The Chemours (NYSE:CC)
The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Fluoroproducts, and Chemical Solutions. The Titanium Technologies segment manufactures and sells titanium dioxide under the Ti-Pure and BaiMax brands for various applications in architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride window profiles, laminate papers used for furniture and building materials, and coated papers and paperboards used for packaging. The Fluoroproducts segment provides fluoroproducts, including refrigerants, and industrial fluoropolymer resins and derivatives under the Teflon, Viton, Krytox, and Nafion brand names. The Chemical Solutions segment offers industrial and specialty chemicals for gold production, oil and gas, water treatment, electronics, and automotive industries. It also provides sodium cyanide through its mining solutions business; and performance chemicals and intermediates, such as methylamines, glycolic acid, and Vazo free radical initiators. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware.
Industry, Sector and Symbol
Industry Chemicals & allied products
Sub-IndustryN/A
SectorBasic Materials
SymbolNYSE:CC
CUSIPN/A
Phone302-773-1000
Debt
Debt-to-Equity Ratio4.13
Current Ratio2.21
Quick Ratio1.60
Price-To-Earnings
Trailing P/E Ratio13.75
Forward P/E Ratio9.23
P/E Growth0.59
Sales & Book Value
Annual Sales$6.18 billion
Price / Sales1.51
Cash Flow$5.5168 per share
Price / Cash9.52
Book Value$4.67 per share
Price / Book11.25
Profitability
EPS (Most Recent Fiscal Year)$3.82
Net Income$746 million
Net Margins13.79%
Return on Equity107.89%
Return on Assets12.09%
Miscellaneous
Employees7,000
Outstanding Shares177,910,000
The Chemours (NYSE:CC) Frequently Asked Questions
What is The Chemours' stock symbol?
The Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."
How often does The Chemours pay dividends? What is the dividend yield for The Chemours?
The Chemours announced a quarterly dividend on Tuesday, May 1st. Shareholders of record on Thursday, May 17th will be given a dividend of $0.17 per share on Friday, June 15th. This represents a $0.68 dividend on an annualized basis and a yield of 1.29%. The ex-dividend date is Wednesday, May 16th. View The Chemours' Dividend History.
How will The Chemours' stock buyback program work?
The Chemours announced that its Board of Directors has authorized a share buyback plan on Monday, December 4th 2017, which authorizes the company to repurchase $500,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase shares of its stock through open market purchases. Shares repurchase plans are often a sign that the company's leadership believes its stock is undervalued.
How were The Chemours' earnings last quarter?
The Chemours Company (NYSE:CC) announced its quarterly earnings data on Thursday, May, 3rd. The specialty chemicals company reported $1.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $1.22 by $0.19. The specialty chemicals company earned $1.73 billion during the quarter, compared to analyst estimates of $1.65 billion. The Chemours had a return on equity of 107.89% and a net margin of 13.79%. The firm's quarterly revenue was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.75 EPS. View The Chemours' Earnings History.
When is The Chemours' next earnings date?
What price target have analysts set for CC?
10 Wall Street analysts have issued 12 month price objectives for The Chemours' stock. Their predictions range from $55.00 to $69.00. On average, they anticipate The Chemours' stock price to reach $60.9444 in the next twelve months. View Analyst Ratings for The Chemours.
Who are some of The Chemours' key competitors?
Some companies that are related to The Chemours include Asahi Kasei (AHKSY), DSM (RDSMY), FMC (FMC), Johnson Matthey (JMPLY), Huntsman (HUN), Olin (OLN), W. R. Grace and (GRA), Ashland (ASH), Univar (UNVR), Ingevity (NGVT), Balchem (BCPC), GCP Applied Technologies (GCP), PQ Group (PQG), Innospec (IOSP) and KMG Chemicals (KMG).
Who are The Chemours' key executives?
The Chemours' management team includes the folowing people:
- Mr. Mark P. Vergnano, Pres, CEO & Director (Age 60)
- Mr. Mark E. Newman, Sr. VP & CFO (Age 55)
- Mr. David C. Shelton Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 54)
- Mr. E. Bryan Snell, Pres of Titanium Technologies (Age 61)
- Mr. Paul Kirsch, Pres of Fluoroproducts Bus. (Age 54)
Has The Chemours been receiving favorable news coverage?
Press coverage about CC stock has been trending somewhat positive this week, according to Accern. Accern identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. The Chemours earned a media sentiment score of 0.20 on Accern's scale. They also gave media coverage about the specialty chemicals company an impact score of 46.55 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.
Who are The Chemours' major shareholders?
The Chemours' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (9.88%), Iridian Asset Management LLC CT (2.56%), Prudential Financial Inc. (2.16%), Allianz Asset Management GmbH (1.39%), Northern Trust Corp (0.96%) and Point72 Asset Management L.P. (0.92%). Company insiders that own The Chemours stock include Amy Trojanowski, Christian W Siemer, David C Shelton, E Bryan Snell, Erich Parker, Mark Newman, Mark P Vergnano, Paul Kirsch and Richard H Brown. View Institutional Ownership Trends for The Chemours.
Which institutional investors are selling The Chemours stock?
CC stock was sold by a variety of institutional investors in the last quarter, including Columbus Circle Investors, Natixis, Hsbc Holdings PLC, JPMorgan Chase & Co., Spark Investment Management LLC, Caisse DE Depot ET Placement DU Quebec, Thrivent Financial for Lutherans and Swiss National Bank. Company insiders that have sold The Chemours company stock in the last year include Amy Trojanowski, Christian W Siemer, David C Shelton, E Bryan Snell, Erich Parker, Mark Newman, Mark P Vergnano and Paul Kirsch. View Insider Buying and Selling for The Chemours.
Which institutional investors are buying The Chemours stock?
CC stock was acquired by a variety of institutional investors in the last quarter, including Iridian Asset Management LLC CT, First Eagle Investment Management LLC, Point72 Asset Management L.P., Millennium Management LLC, Scopus Asset Management L.P., Carillon Tower Advisers Inc., Allianz Asset Management GmbH and LSV Asset Management. View Insider Buying and Selling for The Chemours.
How do I buy shares of The Chemours?
Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is The Chemours' stock price today?
One share of CC stock can currently be purchased for approximately $52.52.
How big of a company is The Chemours?
The Chemours has a market capitalization of $9.28 billion and generates $6.18 billion in revenue each year. The specialty chemicals company earns $746 million in net income (profit) each year or $3.82 on an earnings per share basis. The Chemours employs 7,000 workers across the globe.
How can I contact The Chemours?
The Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19899. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]
MarketBeat Community Rating for The Chemours (CC)
MarketBeat's community ratings are surveys of what our community members think about The Chemours and other stocks. Vote "Outperform" if you believe CC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CC will underperform the S&P 500 over the long term. You may vote once every thirty days.
The Chemours (NYSE:CC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
10 Wall Street analysts have issued ratings and price targets for The Chemours in the last 12 months. Their average twelve-month price target is $60.9444, suggesting that the stock has a possible upside of 16.04%. The high price target for CC is $69.00 and the low price target for CC is $55.00. There are currently 3 hold ratings and 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.70 | 2.70 | 2.67 | 2.88 |
| Ratings Breakdown: | 0 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
3 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $60.9444 | $59.65 | $57.9444 | $53.50 |
| Price Target Upside: | 16.04% upside | 22.41% upside | 8.13% upside | 3.18% upside |
The Chemours (NYSE:CC) Consensus Price Target History
The Chemours (NYSE:CC) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
The Chemours (NYSE:CC) Dividend Information
The Chemours pays an annual dividend of $0.68 per share, with a dividend yield of 1.29%. CC's next quarterly dividend payment will be made on Friday, June 15. The Chemours pays out 17.80% of its earnings out as a dividend.
| Next Dividend: | 6/15/2018 |
| Annual Dividend: | $0.68 |
| Dividend Yield: | 1.29% |
| Dividend Growth: | 0.00% (3 Year Average) |
| Payout Ratio(s): | 17.80% (Trailing 12 Months of Earnings)
11.95% (Based on This Year's Estimates)
10.78% (Based on Next Year's Estimates)
12.33% (Based on Cash Flow)
|
| Frequency: | Quarterly Dividend |
The Chemours (NYSE:CC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
| 5/1/2018 | quarterly | $0.17 | 1.41% | 5/16/2018 | 5/17/2018 | 6/15/2018 |
| 12/1/2017 | Quarterly | $0.17 | 1.43% | 2/14/2018 | 2/15/2018 | 3/15/2018 |
| 11/7/2017 | quarterly | $0.03 | 0.24% | 11/17/2017 | 11/20/2017 | 12/15/2017 |
| 8/2/2017 | quarterly | $0.03 | 0.25% | 8/15/2017 | 8/17/2017 | 9/15/2017 |
| 4/27/2017 | quarterly | $0.03 | 0.3% | 5/15/2017 | 5/17/2017 | 6/15/2017 |
| 2/14/2017 | quarterly | $0.03 | 0.37% | 2/23/2017 | 2/27/2017 | 3/15/2017 |
| 11/2/2016 | quarterly | $0.03 | 0.72% | 11/15/2016 | 11/17/2016 | 12/15/2016 |
| 8/3/2016 | quarterly | $0.03 | 1.34% | 8/15/2016 | 8/17/2016 | 9/15/2016 |
| 4/27/2016 | quarterly | $0.03 | 1.27% | 5/13/2016 | 5/17/2016 | 6/15/2016 |
| 2/23/2016 | quarterly | $0.03 | 2.44% | 3/9/2016 | 3/11/2016 | 3/31/2016 |
| 9/1/2015 | quarterly | $0.03 | 1.38% | 11/10/2015 | 11/13/2015 | 12/14/2015 |
| 7/24/2015 | special | $0.55 | | 7/30/2015 | 8/3/2015 | 9/11/2015 |
(Data available from 1/1/2013 forward)
The Chemours (NYSE CC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 1.75%
Institutional Ownership Percentage: 76.78%
The Chemours (NYSE CC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/9/2018 | Mark P Vergnano | Insider | Sell | 200,151 | $50.47 | $10,101,620.97 | 394,299 |  |
| 5/8/2018 | Mark Newman | CFO | Sell | 43,675 | $50.04 | $2,185,497.00 | 125,399 | |
| 4/17/2018 | Erich Parker | SVP | Sell | 5,000 | $52.00 | $260,000.00 | | |
| 3/9/2018 | Mark Newman | VP | Sell | 29,381 | $49.19 | $1,445,251.39 | | |
| 2/20/2018 | Paul Kirsch | Insider | Sell | 13,770 | $50.01 | $688,637.70 | 63,093 | |
| 12/13/2017 | Christian W. Siemer | Insider | Sell | 15,088 | $47.37 | $714,718.56 | | |
| 11/6/2017 | E Bryan Snell | Insider | Sell | 11,878 | $53.25 | $632,503.50 | 63,063 | |
| 10/13/2017 | David C Shelton | SVP | Sell | 5,908 | $56.01 | $330,907.08 | 47,356 | |
| 10/10/2017 | David C Shelton | SVP | Sell | 13,397 | $55.00 | $736,835.00 | | |
| 10/5/2017 | David C Shelton | SVP | Sell | 19,000 | $53.68 | $1,019,920.00 | | |
| 9/5/2017 | E Bryan Snell | Insider | Sell | 13,000 | $49.35 | $641,550.00 | | |
| 8/31/2017 | David C. Shelton | SVP | Sell | 13,337 | $48.48 | $646,577.76 | | |
| 8/11/2017 | Amy Trojanowski | VP | Sell | 2,500 | $46.03 | $115,075.00 | | |
| 8/11/2017 | E Bryan Snell | Insider | Sell | 10,000 | $46.24 | $462,400.00 | | |
| 6/5/2017 | Paul Kirsch | Insider | Sell | 19,036 | $41.42 | $788,471.12 | | |
| 5/16/2017 | Erich Parker | VP | Sell | 4,908 | $45.53 | $223,461.24 | | |
| 5/5/2017 | Mark Newman | VP | Sell | 22,781 | $39.83 | $907,367.23 | | |
| 5/3/2017 | Richard H. Brown | Director | Buy | 2,500 | $39.10 | $97,750.00 | | |
| 5/13/2016 | Mark Newman | CFO | Buy | 2,800 | $9.71 | $27,188.00 | 108,533 | |
| 5/4/2016 | Bradley J Bell | Director | Buy | 10,000 | $9.65 | $96,500.00 | 21,747 | |
| 2/26/2016 | Stephen D. Newlin | Director | Buy | 10,000 | $4.94 | $49,400.00 | | |
| 11/23/2015 | Thierry Fj Vanlancker | Insider | Buy | 15,000 | $6.00 | $90,000.00 | 190,022 | |
| 9/14/2015 | E Bryan Snell | Insider | Buy | 8,000 | $8.89 | $71,120.00 | 22,051 | |
| 9/11/2015 | Amy Trojanowski | VP | Buy | 5,400 | $9.24 | $49,896.00 | 11,982 | |
| 9/10/2015 | Christian W Siemer | Insider | Buy | 10,100 | $9.39 | $94,839.00 | 31,843 | |
| 9/9/2015 | Mark Newman | CFO | Buy | 10,600 | $9.32 | $98,792.00 | 114,109 | |
| 9/8/2015 | Christian W Siemer | Insider | Buy | 11,000 | $9.11 | $100,210.00 | 21,743 | |
| 9/4/2015 | David C Shelton | SVP | Buy | 5,000 | $9.00 | $45,000.00 | 13,183 | |
| 9/4/2015 | Mark P Vergnano | CEO | Buy | 72,600 | $9.25 | $671,550.00 | 321,337 | |
| 9/4/2015 | Stephen D. Newlin | Director | Buy | 7,000 | $9.18 | $64,260.00 | 16,680 | |
(Data available from 1/1/2013 forward)
The Chemours (NYSE CC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Chemours Makes Fortune 500 List a Second Consecutive Year
www.prnewswire.com - May 21 at 8:51 PM |
 | Chemours Company, (The) -- Moody's assigns Ba3 to Chemours' New Senior Unsecured Notes
finance.yahoo.com - May 21 at 4:16 PM |
 | The Chemours (CC) Earns Buy Rating from Analysts at Vertical Research
www.americanbankingnews.com - May 21 at 10:54 AM |
 | BRIEF-Chemours Announces Commencement Of Public Offering Of Senior Notes
www.reuters.com - May 21 at 9:46 AM |
 | Yamana Gold (AUY) Produces First Gold & Silver at Cerro Moro
www.zacks.com - May 21 at 9:46 AM |
| Has Chemours (CC) Outpaced Other Basic Materials Stocks This Year?
www.zacks.com - May 21 at 9:46 AM |
| The Chemours Company Announces Conditional Cash Tender Offer And Consent Solicitation Of Up To $250,000,000 Of 6.625% Senior Notes Maturing In 2023
finance.yahoo.com - May 21 at 9:45 AM |
| The Chemours Company Announces Conditional Cash Tender Offer And Consent Solicitation And Redemption Of 6.125% Senior Notes Maturing In 2023
finance.yahoo.com - May 21 at 9:45 AM |
| Inspire Awards 2018: Mary Cranston on why women need to push back on stereotypes about leadership
finance.yahoo.com - May 17 at 4:13 PM |
| The Chemours Company's Barbara H. Minor Awarded Prestigious Perkin Medal
finance.yahoo.com - May 17 at 4:13 PM |
| Zacks.com highlights: Chemours, Boise Cascade, Louisiana-Pacific, Seagate Technology and Meet Group
finance.yahoo.com - May 16 at 4:19 PM |
 | Form 4 Chemours Co For: May 08 Filed by: Newman Mark
www.streetinsider.com - May 11 at 4:25 PM |
| Insider Selling: The Chemours Company (CC) CFO Sells 43,675 Shares of Stock
www.americanbankingnews.com - May 10 at 10:32 PM |
| The Chemours Company (CC) Insider Sells $10,101,620.97 in Stock
www.americanbankingnews.com - May 10 at 10:14 PM |
| Chemours (CC) PT Raised to $70 at BMO Capital; Remains Top Pick
www.streetinsider.com - May 8 at 4:17 PM |
| The Chemours' (CC) Buy Rating Reiterated at Barclays
www.americanbankingnews.com - May 8 at 3:45 PM |
| The Chemours (CC) Price Target Increased to $69.00 by Analysts at Citigroup
www.americanbankingnews.com - May 8 at 11:02 AM |
| Chemours Announces Sodium Cyanide Price Increase
finance.yahoo.com - May 8 at 9:41 AM |
| Has Chemours Company (CC) Outpaced Other Basic Materials Stocks This Year?
finance.yahoo.com - May 7 at 10:10 AM |
| Form 4 Chemours Co For: May 02 Filed by: Farrell Dawn L
www.streetinsider.com - May 6 at 4:21 PM |
| Edited Transcript of CC earnings conference call or presentation 4-May-18 12:30pm GMT
finance.yahoo.com - May 5 at 9:56 AM |
| Financial Comparison: The Chemours (CC) and Johnson Matthey (JMPLY)
www.americanbankingnews.com - May 4 at 5:29 PM |
| The Chemours Company Reports First Quarter 2018 Results, Doubling Earnings Year-over-Year
finance.yahoo.com - May 4 at 4:19 PM |
| Chemours: 1Q Earnings Snapshot
finance.yahoo.com - May 4 at 9:33 AM |
 | Chemours beats by $0.20, beats on revenue
seekingalpha.com - May 4 at 9:33 AM |
| The Chemours Company Names Jonathan Lock as Vice President of Corporate Development and Investor Relations
www.prnewswire.com - May 4 at 7:30 AM |
| The Chemours (CC) Releases Quarterly Earnings Results, Beats Estimates By $0.29 EPS
www.americanbankingnews.com - May 4 at 12:30 AM |
| The Chemours Company Declares Quarterly Dividend of $0.17 (CC)
www.americanbankingnews.com - May 1 at 9:30 PM |
| The Chemours Company (CC) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 30 at 1:36 PM |
 | Notable Two Hundred Day Moving Average Cross - CC
www.nasdaq.com - April 27 at 4:05 PM |
| The Chemours (CC) & Innospec (IOSP) Financial Contrast
www.americanbankingnews.com - April 26 at 7:46 AM |
| The Chemours (CC) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - April 26 at 1:41 AM |
| Chemours CEO Receives Top Industry Honor for Innovation & Professional Impact
finance.yahoo.com - April 23 at 9:56 AM |
| The Chemours (CC) Stock Rating Reaffirmed by UBS
www.americanbankingnews.com - April 20 at 9:46 PM |
| The Chemours Company (CC) SVP Sells $260,000.00 in Stock
www.americanbankingnews.com - April 19 at 10:10 PM |
| Chemours (CC) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 18 at 6:54 PM |
 | 'Fast and loose': Plaintiffs respond to motion to dismiss GenX case
www.bizjournals.com - April 17 at 9:53 AM |
| 'Fast and loose': Plaintiffs respond to motion to dismiss GenX case
finance.yahoo.com - April 16 at 4:22 PM |
| Jefferies Group Raises Chemours (CC) Price Target to $60.00
www.americanbankingnews.com - April 13 at 7:49 PM |
| Chemours (CC) Rating Increased to Neutral at UBS
www.americanbankingnews.com - April 13 at 12:58 AM |
| June 1st Options Now Available For Chemours (CC)
www.nasdaq.com - April 12 at 4:19 PM |
| Why Chemours Company (CC) Could Beat Earnings Estimates Again April 11, 2018
www.zacks.com - April 12 at 10:38 AM |
| Why Chemours Company (CC) Could Beat Earnings Estimates Again
finance.yahoo.com - April 11 at 10:28 AM |
| Citigroup Lowers Chemours (CC) Price Target to $66.00
www.americanbankingnews.com - April 10 at 11:29 AM |
| NC puts Chemours on notice over GenX air emissions
www.bizjournals.com - April 9 at 4:16 PM |
| Why Chemours Company (CC) Could Be an Impressive Growth Stock April 09, 2018
www.zacks.com - April 9 at 4:16 PM |
| Analyzing Innospec (IOSP) and Chemours (CC)
www.americanbankingnews.com - April 6 at 9:26 PM |
| Chemours Co (CC) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - April 5 at 1:44 PM |
| Top Ranked Value Stocks to Buy for April 5th
finance.yahoo.com - April 5 at 8:49 AM |
| Is Chemours (CC) a Great Stock for Value Investors?
www.nasdaq.com - April 4 at 5:14 PM |
The Chemours (NYSE:CC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
The Chemours (NYSE:CC) Income Statement, Balance Sheet and Cash Flow Statement
The Chemours (NYSE CC) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
